Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4345-9. doi: 10.1016/j.bmcl.2005.06.072.

Abstract

The SAR of a series of potent sulfonamide hydroxamate TACE inhibitors bearing a butynyloxy P1' group was explored. In particular, compound 5k has excellent in vitro potency against TACE enzyme and in cells, and oral activity in an in vivo model of TNF-alpha production and a collagen-induced arthritis model.

MeSH terms

  • ADAM Proteins / antagonists & inhibitors*
  • ADAM17 Protein
  • Animals
  • Biological Availability
  • Caspase Inhibitors
  • Cell Line
  • Crystallography, X-Ray
  • Cysteine Proteinase Inhibitors / chemical synthesis*
  • Cysteine Proteinase Inhibitors / pharmacokinetics
  • Cysteine Proteinase Inhibitors / pharmacology
  • Dogs
  • Humans
  • Hydroxamic Acids / chemical synthesis*
  • Hydroxamic Acids / pharmacokinetics
  • Hydroxamic Acids / pharmacology
  • Inhibitory Concentration 50
  • Lipopolysaccharides / pharmacology
  • Mice
  • Molecular Structure
  • Monocytes
  • Rats
  • Species Specificity
  • Structure-Activity Relationship
  • Sulfonamides / chemical synthesis*
  • Sulfonamides / pharmacokinetics
  • Sulfonamides / pharmacology
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / drug effects

Substances

  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors
  • Hydroxamic Acids
  • Lipopolysaccharides
  • Sulfonamides
  • Tumor Necrosis Factor-alpha
  • ADAM Proteins
  • ADAM17 Protein
  • ADAM17 protein, human
  • Adam17 protein, mouse
  • Adam17 protein, rat